SAN FRANCISCO, Jan 10 – Celera Genomics on Wednesday announced moves that signal the beginning of the company's foray into the drug target discovery sector.

"We are looking to identify new drug targets," Peter Chambre, Celera’s chief operating officer, said at a company presentation at the JP Morgan H&Q conference.

As part of that move, Celera also announced on Wednesday that it had hired Stephen Hoffman, a pioneer in the development of DNA vaccines, as its senior vice president of immunotherapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.